Biodesix (NASDAQ:BDSX) Reaches New 52-Week High at $20.98


Share on StockTwits

Biodesix, Inc. (NASDAQ:BDSX)’s share price hit a new 52-week high on Thursday . The company traded as high as $20.98 and last traded at $20.98, with a volume of 2052 shares trading hands. The stock had previously closed at $18.87.

A number of brokerages recently weighed in on BDSX. BTIG Research began coverage on shares of Biodesix in a research note on Monday, November 23rd. They issued a “buy” rating and a $22.00 price target on the stock. Morgan Stanley began coverage on shares of Biodesix in a research note on Monday, November 23rd. They issued an “overweight” rating and a $20.00 price target on the stock. Canaccord Genuity began coverage on shares of Biodesix in a research note on Monday, November 23rd. They issued a “buy” rating and a $26.00 price target on the stock. Finally, William Blair began coverage on shares of Biodesix in a research note on Monday, November 23rd. They issued an “outperform” rating on the stock.

The stock has a 50 day moving average of $16.40.

Biodesix (NASDAQ:BDSX) last released its earnings results on Thursday, December 10th. The company reported ($31.93) earnings per share for the quarter. The business had revenue of $9.19 million for the quarter, compared to analyst estimates of $7.78 million. Analysts forecast that Biodesix, Inc. will post -5.66 EPS for the current fiscal year.

About Biodesix (NASDAQ:BDSX)

Biodesix, Inc operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions.

Recommended Story: How Important is Technical Analysis of Stocks

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.